<h4>Background/objective</h4>Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) remains a fundamental diagnostic tool for Prostate cancer (PCa), yet its use is frequently constrained by the high costs and infrastructure requirements of PET imaging. Here, FOLH1 is linked to prostate carcinoma.